TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00655681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamidronate
Description: The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children \< 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
Study: NCT01168310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhalation Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation Solution
Study: NCT03101722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTHE and Huperzine A
Description: huperzine A intervention

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: BTHE and Huperzine A
Description: huperzine A intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BETH
Description: basic treatment and health education

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: BETH
Description: basic treatment and health education
Study: NCT01595958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardio-pulmonary resuscitation
Description: usual care of cardiac arrest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardio-pulmonary resuscitation
Description: usual care of cardiac arrest
Study: NCT00900757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO)
Description: Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
Study: NCT02142361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Silicone hydrogel toric lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Silicone hydrogel toric lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Silicone hydrogel toric lenses.
Study: NCT01004406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intensive LDL-lowering therapy
Description: The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Study: NCT00787098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETM protocol
Description: ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
Study: NCT03770416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00643461

Intervention type: DEVICE
Intervention: Adhesive A
Description: Applied per manufacturer's instructions.

Intervention type: DEVICE
Intervention: Adhesive B
Description: Applied per manufacturer's instructions.

Intervention type: DEVICE
Intervention: Adhesive C
Description: Applied per manufacturer's instructions.
Study: NCT01088243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Study: NCT03867149

Intervention type: OTHER
Group type: OTHER
Intervention: neuroimaging
Description: neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
Study: NCT03770013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: add placebo 9normal saline)
Study: NCT02947464

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical practice
Description: Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical practice + Rapid Maxillary Expansion
Description: Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
Study: NCT01163903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole sodium for injection
Description: Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride injection
Description: 60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
Study: NCT01862458

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tPA alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tPA plus dornase
Study: NCT03867149

Intervention type: OTHER
Group type: OTHER
Intervention: neuroimaging
Description: neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Description: neuropsychological assessment of memory, language, executive functions and mood

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Description: neuropsychological assessment of memory, language, executive functions and mood
Study: NCT04325698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06439535 (CN)
Description: 15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab-EU
Description: 15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Study: NCT03764358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous Fistula
Description: Surgical implantation of an arteriovenous fistula for hemodialysis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tunneled Cuffed Catheter
Description: Placement of a tunneled cuffed catheter in surgical theatre
Study: NCT01556074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga treatment
Description: Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
Study: NCT02391935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCS-01
Description: Cultured, autologous hair follicle cells suspended in cryomedium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cryomedium
Study: NCT06619795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
Study: NCT02391935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cryomedium

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: skin penetration of the needle without injection of liquid
Study: NCT00422344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Sunitinib
Description: Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
Study: NCT03350061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSY
Description: The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
Study: NCT02529904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 - ATIV
Description: All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV.
Study: NCT02409381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motore
Description: 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alivium
Description: 600 mg
Study: NCT03203759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home hospitalization
Description: See above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional inpatient hospitalization
Description: See above
Study: NCT03439215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
Study: NCT00036491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects received four weekly infusions of rituximab at a dose of 375 mg/m\^2
Study: NCT04511962

Intervention type: OTHER
Intervention: Tele-Pulmonary rehabilitation
Description: The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.

Intervention type: OTHER
Intervention: Tele-Pulmonary rehabilitation
Description: The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
Study: NCT01437709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab (This arm is closed)
Description: Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ofatumumab + Bendamustine
Description: Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 \& 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
Study: NCT00738881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT00370981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pagoclone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pagoclone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pagoclone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pagoclone
Study: NCT00477750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Phase I - dose escalating: 5mg/m\^2 dose level -1, 5 mg/m\^2 dose level 0, 8 mg/m\^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m\^2 orally days 1-4 every 28 days until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/m\^2, orally days 1-4 every 28 days until progression
Study: NCT00278148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC2 weekly x 3 weeks
Study: NCT02391935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: skin penetration of the needle without injection of liquid
Study: NCT03687268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone HCl PR tablets
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone HCl PR tablets
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT02342925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Description: 647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Description: 647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: Oral administration twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Single 850 mg dose of metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Single 850 mg dose of metformin
Study: NCT01288781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose monohydrate
Description: During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
Study: NCT03514862

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Booster Training
Description: Four additional mindfulness booster sessions after the 4-week MBI program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Booster Training
Description: Four additional mindfulness booster sessions after the 4-week MBI program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI)
Description: MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Practice
Description: 4 weeks of self-practice after the MBI training.
Study: NCT00649389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: 40mg olmesartan medoxomil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Description: 40mg olmesartan medoxomil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Description: 40mg olmesartan medoxomil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg
Study: NCT03326193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
Study: NCT03390933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.